- Home
- ZS vs WAT Comparison
ZS vs WAT Comparison
Compare ZS & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZS
- WAT
- Stock Information
- Founded
- ZS 2007
- WAT 1958
- Country
- ZS United States
- WAT United States
- Employees
- ZS N/A
- WAT N/A
- Industry
- ZS EDP Services
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- ZS Technology
- WAT Industrials
- Exchange
- ZS Nasdaq
- WAT Nasdaq
- Market Cap
- ZS 45.0B
- WAT 17.8B
- IPO Year
- ZS 2018
- WAT 1995
- Fundamental
- Price
- ZS $279.46
- WAT $303.66
- Analyst Decision
- ZS Buy
- WAT Hold
- Analyst Count
- ZS 33
- WAT 14
- Target Price
- ZS $312.16
- WAT $374.07
- AVG Volume (30 Days)
- ZS 1.8M
- WAT 582.8K
- Earning Date
- ZS 09-02-2025
- WAT 10-31-2025
- Dividend Yield
- ZS N/A
- WAT N/A
- EPS Growth
- ZS N/A
- WAT 10.77
- EPS
- ZS N/A
- WAT 11.09
- Revenue
- ZS $2,673,115,000.00
- WAT $3,046,056,000.00
- Revenue This Year
- ZS $23.45
- WAT $7.19
- Revenue Next Year
- ZS $19.85
- WAT $6.40
- P/E Ratio
- ZS N/A
- WAT $27.46
- Revenue Growth
- ZS 23.31
- WAT 5.89
- 52 Week Low
- ZS $164.78
- WAT $275.05
- 52 Week High
- ZS $318.46
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- ZS 50.28
- WAT 53.25
- Support Level
- ZS $276.31
- WAT $294.96
- Resistance Level
- ZS $289.58
- WAT $303.24
- Average True Range (ATR)
- ZS 9.24
- WAT 9.27
- MACD
- ZS 1.21
- WAT 0.81
- Stochastic Oscillator
- ZS 58.57
- WAT 69.33
About ZS Zscaler Inc.
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.